卡络磺钠联合孟鲁司特钠治疗儿童过敏性紫癜疗效观察

Effect of montelukast sodium combined with caroxonate sodium sulfonate on children with anaphylactoid purpura

目的探讨儿童过敏性紫癜采用卡络磺钠联合孟鲁司特钠治疗的疗效及对血清炎症因子、信号转导抑制蛋白3(suppressor of cytokine signaling 3,SOCS3)和低糖基化IgA1(galactose deficient-IgA1,Gd-IgA1)水平的影响。方法选取2021年8月—2022年12月濮阳市中医医院收治的过敏性紫癜患儿94例,依据治疗方法不同分组,两组给予相同的基础治疗,将采用孟鲁司特钠进行治疗的47例作为对照组,采用孟鲁司特钠联合卡络磺钠进行治疗的47例作为研究组,比较两组疗效、血清细胞因子和Gd-IgA1水平、SOCS3的表达水平、临床症状消退时间及不良反应。结果研究组治疗总有效率97.87%,高于对照组(85.11%)(P<0.05)。两组患儿治疗前肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、Gd-IgA1和SOCS3 mRNA水平比较无统计学意义(P>0.05),治疗后均下降,且研究组治疗后TNF-α、IL-6、Gd-IgA1和SOCS3 mRNA水平(12.11±5.24)ng/mL、(18.96±5.84)pg/mL、(0.09±0.01)U及(1.48±0.19),均低于对照组(P<0.05)。研究组治疗后皮肤紫癜、皮疹、关节痛和腹痛消退时间为(4.79±1.76)d、(5.44±1.38)d、(5.01±1.69)d及(3.47±1.06)d,均短于对照组(P<0.05)。研究组不良反应发生率17.02%,高于对照组的14.89%,但差异无统计学意义(P>0.05)。结论孟鲁司特钠联合卡络磺钠用于儿童过敏性紫癜治疗,具有一定疗效,对于患儿炎症缓解、症状改善意义明显。

Objective To investigate the therapeutic effect of montelukast sodium combined with carbosulfonate sodium sulfonate in the treatment of children with anaphylactoid purpura and the effects on the levels of serum cytokines,suppressor of cytokine signaling 3(SOCS3)and galactose deficient-IgA1(Gd-IgA1).Methods A total of 94 children with anaphylactoid purpura admitted to Chinese Medicine Hospital of Puyang from August 2021 to December 2022 were selected and divided into two groups according to different treatment methods.The two groups were given the same basic treatment.47 cases treated with montelukast sodium were taken as the control group,and 47 cases treated with montelukast sodium combined with caroxulfonate sodium were taken as the study group.The therapeutic effect,serum cytokine and Gd-IgA1 levels,SOCS3 expression levels,clinical symptoms resolution time and adverse reactions were compared between the two groups.Results The total effective rate of the study group was 97.87%,which was higher than that of the control group(85.11%)(P<0.05).The mRNA levels of tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),Gd-IgA1 and SOCS3 in two groups were not statistically significant before treatment(P>0.05),but decreased after treatment.The mRNA levels of TNF-α,IL-6,Gd-IgA1 and SOCS3 in the study group after treatment were(12.11±5.24)ng/mL,(18.96±5.84)pg/mL,(0.09±0.01)U and(1.48±0.19)lower than those in the control group(P<0.05).After treatment,the remission time of skin purpura,rash,arthralgia and abdominal pain in the study group was(4.79±1.76)d,(5.44±1.38)d,(5.01±1.69)d and(3.47±1.06)d,which were shorter than those in the control group(P<0.05).The incidence of adverse reactions in the study group was 17.02%,higher than that in the control group(14.89%),but the difference was not statistically significant(P>0.05).Conclusion Montelukast sodium combined with caroxulfonate sodium sulfonate in the treatment of children with anaphylactoid purpura can obtain significant curative effect,and has obvious significance in relieving inflammation and improving symptoms in children.